55 results
424B5
OGEN
Oragenics Inc
29 Feb 24
Prospectus supplement for primary offering
4:41pm
and approved by the Alfred Ethics Committee in Australia.
The Phase 1 study was double-blinded, randomized and placebo controlled (3:1, drug:placebo
424B5
OGEN
Oragenics Inc
27 Feb 24
Prospectus supplement for primary offering
5:04pm
government on all Research and Development performed in Australia. A comprehensive Investigator’s Brochure was created and approved by the Alfred Ethics
8-K
OGEN
Oragenics Inc
16 Jan 24
Other Events
9:10am
by the Alfred Ethics Committee in Australia.
The Phase 1 study was double-blinded, randomized and placebo controlled (3:1, drug:placebo). Phase 1 used
424B5
OGEN
Oragenics Inc
16 Jan 24
Prospectus supplement for primary offering
9:04am
on all Research and Development performed in Australia. A comprehensive Investigator’s Brochure was created and approved by the Alfred Ethics Committee
8-K
EX-2.1
t9w6pgm 5ueyzf4kb
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am